Products & Services · Accrued and other liabilities
Axatilimab - Development Activities — Accrued and other liabilities
Incyte Axatilimab - Development Activities — Accrued and other liabilities decreased by 41.7% to $1.4M in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ4 2024
Last reportedQ1 2026Apr 28, 2026
Rolls up toAccrued Expenses
How to read this metric
An increase typically signals intensified clinical trial activity or upcoming regulatory milestones, while a decrease may indicate the completion of specific development phases or the settlement of major vendor invoices.
Detailed definition
This metric represents the outstanding financial obligations and liabilities specifically attributed to the research and...
Peer comparison
Comparable to accrued R&D liabilities for specific drug candidates at other biopharmaceutical firms, often categorized under 'Accrued Clinical Trial Expenses' or 'Program-Specific R&D Accruals'.
Metric ID:
incy_segment_axatilimab_development_activities_accrued_and_other_liabilitiesHistorical Data
3 periods
| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $2.2M | $2.4M | $1.4M |
| QoQ Change | — | +9.1% | -41.7% |
| YoY Change | — | +9.1% | — |
Range$1.4M – $2.4M
Avg YoY Growth+9.1%
Median YoY Growth+9.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's axatilimab - development activities — accrued and other liabilities?
- Incyte (INCY) reported axatilimab - development activities — accrued and other liabilities of $1.4M in Q1 2026.
- What does axatilimab - development activities — accrued and other liabilities mean?
- The total unpaid expenses and financial obligations related to the development of the Axatilimab drug candidate.